Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALL-X-HOPE-2025 pediatric acute lymphoblastic leukemia protocol
ChiCTR2600135920Phase 4Recruiting
- Sponsor
- Fujian Children's Hospital
- Start
- Sep 2025
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of venetoclax, blinatumomab, dasatinib and tucidinostat in acute lymphoblastic leukemia (ALL), B cell acute lymphoblastic leukemia (B-ALL) and t-cell acute lymphoblastic leukemia (T-ALL) (5 arms), sponsored by Fujian Children's Hospital. Primary endpoints: MRD-negative remission rate, overall survival and 3 more. Started Sep 2025; status: recruiting.
02
Drugs
venetoclaxblinatumomabdasatinibtucidinostat
03
Conditions
acute lymphoblastic leukemia (ALL)B cell acute lymphoblastic leukemia (B-ALL)t-cell acute lymphoblastic leukemia (T-ALL)
Beyond the preview
Go deeper on ChiCTR2600135920.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600135920.